| Followers | 54 |
| Posts | 6684 |
| Boards Moderated | 0 |
| Alias Born | 01/11/2017 |
Thursday, May 11, 2017 3:32:14 PM
I can only speak from experience being with two companies that were purchased by private equity groups. Basically, an announcement of an agreement will be made with the applicable SEC filings. That would show the price and other specifics, for example is it cash and stock, straight up stock deal or all cash.
Once that occurs, these shares will rocket to close to that price. You can sell your shares at any time during the DD and closing stage. A lot of people play the game of arbitrage buying and selling huge blocks with a few pennies variance.
It's risk/reward. Once you get a good price, you can sell and be guaranteed the amount you sell for. If you hold out, you risk the deal falling apart.
Generally, these discussions begin over "what ifs" between companies, then an NDA will be signed and some sort of exclusivity. I'm certain that when it comes to this, Gilead will also probably sign on to a large settlement price if they choose to back out without cause (financing, they found something that wasn't disclosed etc)
For me, I hope it's a straight up cash deal. I don't want to exchange "x" CYDY shares for "y" GILD shares because they have other issues.
Hope this helps. Keep in mind, pigs get fat, hogs get slaughtered! I sell at a discount if it's guaranteed.
Grip
Once that occurs, these shares will rocket to close to that price. You can sell your shares at any time during the DD and closing stage. A lot of people play the game of arbitrage buying and selling huge blocks with a few pennies variance.
It's risk/reward. Once you get a good price, you can sell and be guaranteed the amount you sell for. If you hold out, you risk the deal falling apart.
Generally, these discussions begin over "what ifs" between companies, then an NDA will be signed and some sort of exclusivity. I'm certain that when it comes to this, Gilead will also probably sign on to a large settlement price if they choose to back out without cause (financing, they found something that wasn't disclosed etc)
For me, I hope it's a straight up cash deal. I don't want to exchange "x" CYDY shares for "y" GILD shares because they have other issues.
Hope this helps. Keep in mind, pigs get fat, hogs get slaughtered! I sell at a discount if it's guaranteed.
Grip
Recent CYDY News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
